Neurexis Therapeutics Awarded NIH Phase I SBIR Grant to Accelerate IND-Enabling Studies of Neuroprotective Therapeutic
Aurora, CO (PRWEB) October 14, 2021 -- Neurexis Therapeutics, Incorporated, announces it has been awarded a $496,145 grant from the National Institute of